Texas telehealth bill removes ‘face-to-face’ requirement

| | Health Exec | Telehealth

Telehealth standards could change in Texas if the state’s legislature passes newly proposed legislation removing the requirement for physicians to meet patients in-person before offering services via telehealth or prescribing any drugs.

The National Law Review reported the bill would remove one of the main reasons Texas has been given the lowest composite score for telehealth access by the American Telemedicine Association. These struggles chiefly rose from the Texas Medical Board’s concerns that Dallas-based Teladoc, one of the largest telehealth providers, would handle writing prescriptions for patients their physicians had never met. Teladoc eventually won the case.

The new bill would still require doctors to establish a relationship with telemedicine patients before ordering drugs, but not via a face-to-face visit.

Read the full article: 

Texas to Take a Leap Forward in Telehealth – A Proposed Bill Drops the Controve…

Related Content

Amazon One Medical sued after patient prescribed inhaler dies in ER
DEA, HHS extend telehealth controlled substance prescription rule
Association of 300 telehealth groups urges Congress to extend COVID-era rules
Eli Lilly releases cheaper, single-use vials of weight loss drug
Walmart sells virtual care business to Fabric
AMA will aggressively support permanent telemedicine reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.